Poll
Capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC
Dr. Murphy on increasing diversity in cancer clinical trials
FDA accepts sNDA for darolutamide plus ADT in mHSPC
Dr. Schwen on focal therapies for prostate cancer
ECLIPSE trial: 177Lu-PSMA-I&T extends rPFS vs hormone therapy in mCRPC
Study characterizes long-term impact of prostate cancer treatment